Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ludmila Pawlikowska is active.

Publication


Featured researches published by Ludmila Pawlikowska.


Aging Cell | 2009

Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity.

Ludmila Pawlikowska; Donglei Hu; Scott Huntsman; Andrew Sung; Catherine Chu; Justin Chen; Alexander H. Joyner; Nicholas J. Schork; Wen Chi Hsueh; Alex P. Reiner; Bruce M. Psaty; Gil Atzmon; Nir Barzilai; Steven R. Cummings; Warren S. Browner; Pui-Yan Kwok; Elad Ziv

The insulin/IGF1 signaling pathways affect lifespan in several model organisms, including worms, flies and mice. To investigate whether common genetic variation in this pathway influences lifespan in humans, we genotyped 291 common variants in 30 genes encoding proteins in the insulin/IGF1 signaling pathway in a cohort of elderly Caucasian women selected from the Study of Osteoporotic Fractures (SOF). The cohort included 293 long‐lived cases (lifespan ≥ 92 years (y), mean ± standard deviation (SD) = 95.3 ± 2.2y) and 603 average‐lifespan controls (lifespan ≤ 79y, mean = 75.7 ± 2.6y). Variants were selected for genotyping using a haplotype‐tagging approach. We found a modest excess of variants nominally associated with longevity. Nominally significant variants were then replicated in two additional Caucasian cohorts including both males and females: the Cardiovascular Health Study and Ashkenazi Jewish Centenarians. An intronic single nucleotide polymorphism in AKT1, rs3803304, was significantly associated with lifespan in a meta‐analysis across the three cohorts (OR = 0.78 95%CI = 0.68–0.89, adjusted P = 0.043); two intronic single nucleotide polymorphisms in FOXO3A demonstrated a significant lifespan association among women only (rs1935949, OR = 1.35, 95%CI = 1.15–1.57, adjusted P = 0.0093). These results demonstrate that common variants in several genes in the insulin/IGF1 pathway are associated with human lifespan.


Hepatology | 2006

Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency

A.S. Knisely; Sandra Strautnieks; Yvonne Meier; Bruno Stieger; J Byrne; Bernard C. Portmann; Laura N. Bull; Ludmila Pawlikowska; Banu Bilezikçi; Figen Ozcay; Aranka László; László Tiszlavicz; Lynette Moore; Jeremy Raftos; Henrik Arnell; Björn Fischler; Antal Nemeth; Nikos Papadogiannakis; Joanna Cielecka-Kuszyk; Irena Jankowska; Joanna Pawłowska; Hector Melin-Aldana; Karan M. Emerick; Peter F. Whitington; Giorgina Mieli-Vergani; Richard Thompson

Hepatocellular carcinoma (HCC) is rare in young children. We attempted to see if immunohistochemical and mutational‐analysis studies could demonstrate that deficiency of the canalicular bile acid transporter bile salt export pump (BSEP) and mutation in ABCB11, encoding BSEP, underlay progressive familial intrahepatic cholestasis (PFIC)—or “neonatal hepatitis” suggesting PFIC—that was associated with HCC in young children. We studied 11 cases of pediatric HCC in the setting of PFIC or “neonatal hepatitis” suggesting PFIC. Archival liver were retrieved and immunostained for BSEP. Mutational analysis of ABCB11 was performed in leukocyte DNA from available patients and parents. Among the 11 nonrelated children studied aged 13‐52 months at diagnosis of HCC, 9 (and a full sibling, with neonatal hepatitis suggesting PFIC, of a tenth from whom liver was not available) had immunohistochemical evidence of BSEP deficiency; the eleventh child did not. Mutations in ABCB11 were demonstrated in all patients with BSEP deficiency in whom leukocyte DNA could be studied (n = 7). These mutations were confirmed in the parents (n = 14). With respect to the other 3 children with BSEP deficiency, mutations in ABCB11 were demonstrated in all 5 parents in whom leukocyte DNA could be studied. Thirteen different mutations were found. In conclusion, PFIC associated with BSEP deficiency represents a previously unrecognized risk for HCC in young children. Immunohistochemical evidence of BSEP deficiency correlates well with demonstrable mutation in ABCB11. (HEPATOLOGY 2006;44:478–486.)


Gastroenterology | 2008

Severe bile salt export pump deficiency : 82 different ABCB11 mutations in 109 families

Sandra Strautnieks; J Byrne; Ludmila Pawlikowska; Dita Cebecauerová; Anne Rayner; Laura Dutton; Yvonne Meier; Anthony Antoniou; Bruno Stieger; Henrik Arnell; Figen Ozcay; Hussa F. AlHussaini; Atif F Bassas; Henkjan J. Verkade; Björn Fischler; Antal Nemeth; Radana Kotalova; Benjamin L. Shneider; Joanna Cielecka-Kuszyk; Patricia McClean; Peter F. Whitington; Etienne Sokal; Milan Jirsa; Sami Wali; Irena Jankowska; Joanna Pawłowska; Giorgina Mieli-Vergani; A.S. Knisely; Laura N. Bull; Richard Thompson

BACKGROUND & AIMS Patients with severe bile salt export pump (BSEP) deficiency present as infants with progressive cholestatic liver disease. We characterized mutations of ABCB11 (encoding BSEP) in such patients and correlated genotypes with residual protein detection and risk of malignancy. METHODS Patients with intrahepatic cholestasis suggestive of BSEP deficiency were investigated by single-strand conformation polymorphism analysis and sequencing of ABCB11. Genotypes sorted by likely phenotypic severity were correlated with data on BSEP immunohistochemistry and clinical outcome. RESULTS Eighty-two different mutations (52 novel) were identified in 109 families (9 nonsense mutations, 10 small insertions and deletions, 15 splice-site changes, 3 whole-gene deletions, 45 missense changes). In 7 families, only a single heterozygous mutation was identified despite complete sequence analysis. Thirty-two percent of mutations occurred in >1 family, with E297G and/or D482G present in 58% of European families (52/89). On immunohistochemical analysis (88 patients), 93% had abnormal or absent BSEP staining. Expression varied most for E297G and D482G, with some BSEP detected in 45% of patients (19/42) with these mutations. Hepatocellular carcinoma or cholangiocarcinoma developed in 15% of patients (19/128). Two protein-truncating mutations conferred particular risk; 38% (8/21) of such patients developed malignancy versus 10% (11/107) with potentially less severe genotypes (relative risk, 3.7 [confidence limits, 1.7-8.1; P = .003]). CONCLUSIONS With this study, >100 ABCB11 mutations are now identified. Immunohistochemically detectable BSEP is typically absent, or much reduced, in severe disease. BSEP deficiency confers risk of hepatobiliary malignancy. Close surveillance of BSEP-deficient patients retaining their native liver, particularly those carrying 2 null mutations, is essential.


Hepatology | 2004

Characterization of mutations in ATP8B1 associated with hereditary cholestasis

Leo W. J. Klomp; Julie C. Vargas; Saskia W.C. van Mil; Ludmila Pawlikowska; Sandra Strautnieks; Michiel J.T. van Eijk; Jenneke A. Juijn; Carlos R. Pabón-Peña; Lauren B. Smith; Joseph DeYoung; J Byrne; Justijn Gombert; Gerda van der Brugge; Ruud Berger; Irena Jankowska; Joanna Pawłowska; Erica Villa; Alex S. Knisely; Richard Thompson; Nelson B. Freimer; Roderick H. J. Houwen; Laura N. Bull

Progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) are clinically distinct hereditary disorders. PFIC patients suffer from chronic cholestasis and develop liver fibrosis. BRIC patients experience intermittent attacks of cholestasis that resolve spontaneously. Mutations in ATP8B1 (previously FIC1) may result in PFIC or BRIC. We report the genomic organization of ATP8B1 and mutation analyses of 180 families with PFIC or BRIC that identified 54 distinct disease mutations, including 10 mutations predicted to disrupt splicing, 6 nonsense mutations, 11 small insertion or deletion mutations predicted to induce frameshifts, 1 large genomic deletion, 2 small inframe deletions, and 24 missense mutations. Most mutations are rare, occurring in 1–3 families, or are limited to specific populations. Many patients are compound heterozygous for 2 mutations. Mutation type or location correlates overall with clinical severity: missense mutations are more common in BRIC (58% vs. 38% in PFIC), while nonsense, frameshifting, and large deletion mutations are more common in PFIC (41% vs. 16% in BRIC). Some mutations, however, lead to a wide range of phenotypes, from PFIC to BRIC or even no clinical disease. ATP8B1 mutations were detected in 30% and 41%, respectively, of the PFIC and BRIC patients screened. Supplementary material for this article can be found on the HEPATOLOGY website (http://interscience.wiley.com/jpages/0270‐9139/suppmat/index.html) and at www.atp8b1‐primers.nl (HEPATOLOGY 2004;40:27–38.)


American Journal of Human Genetics | 2007

Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels.

David Reich; Nick Patterson; Vijaya Ramesh; Philip L. De Jager; Gavin J. McDonald; Arti Tandon; Edwin Choy; Donglei Hu; Bani Tamraz; Ludmila Pawlikowska; Christina Wassel-Fyr; Scott Huntsman; Alicja Waliszewska; Elizabeth Rossin; Rongling Li; Melissa Garcia; Alex P. Reiner; Robert E. Ferrell; Steve Cummings; Pui-Yan Kwok; Tamara B. Harris; Joseph M. Zmuda; Elad Ziv

Circulating levels of inflammatory markers can predict cardiovascular disease risk. To identify genes influencing the levels of these markers, we genotyped 1,343 single-nucleotide polymorphisms (SNPs) in 1,184 African Americans from the Health, Aging and Body Composition (Health ABC) Study. Using admixture mapping, we found a significant association of interleukin 6 soluble receptor (IL-6 SR) with European ancestry on chromosome 1 (LOD 4.59), in a region that includes the gene for this receptor (IL-6R). Genotyping 19 SNPs showed that the effect is largely explained by an allele at 4% frequency in West Africans and at 35% frequency in European Americans, first described as associated with IL-6 SR in a Japanese cohort. We replicate this association (P<<1.0x10-12) and also demonstrate a new association with circulating levels of a different molecule, IL-6 (P<3.4x10-5). After replication in 1,674 European Americans from Health ABC, the combined result is even more significant: P<<1.0x10-12 for IL-6 SR, and P<2.0x10-9 for IL-6. These results also serve as an important proof of principle, showing that admixture mapping can not only coarsely localize but can also fine map a phenotypically important variant.


American Heart Journal | 2008

Interleukin 6 and Atrial Fibrillation in Patients with Coronary Artery Disease: Data from the Heart and Soul Study

Gregory M. Marcus; Mary A. Whooley; David V. Glidden; Ludmila Pawlikowska; Jonathan G. Zaroff; Jeffrey E. Olgin

BACKGROUND Previous studies suggest that markers of inflammation are elevated in patients with atrial fibrillation (AF). However, because inflammation has been implicated in contributing to risk of both AF and coronary artery disease (CAD), which are often present in the same populations, it is important to control for confounding by the presence of CAD. We therefore examined several biomarkers of inflammation and ultimately genotyped IL-6 polymorphisms in patients with AF in a cohort of subjects with known CAD. METHODS We performed a cross-sectional analysis of 971 participants in the Heart and Soul Study, 46 of whom had AF. Interleukin-6, C-reactive protein, tumor necrosis factor-alpha, CD-40 ligand, monocyte chemoattractant protein-1, and fibrinogen levels were measured. RESULTS In both unadjusted and adjusted analyses, IL-6 was the only biomarker significantly associated with AF (median IL-6 3.76 and 2.52 pg/mL in those with and without AF, respectively, P = .0005; adjusted odds ratio 1.77, P = .032). The IL-6-174CC genotype was significantly associated with the presence of AF in the adjusted analysis (odds ratio 2.34, P = .04) and with higher IL-6 levels (P = .002). CONCLUSIONS In this cohort of subjects with CAD, AF was significantly associated with elevated IL-6 levels and the IL-6-174CC genotype. No associations were found with other biomarkers, including C-reactive protein. This suggests that IL-6 is a uniquely important mediator in the pathophysiology of AF.


Stroke | 2006

Adrenoceptor Polymorphisms and the Risk of Cardiac Injury and Dysfunction After Subarachnoid Hemorrhage

Jonathan G. Zaroff; Ludmila Pawlikowska; Jacob C. Miss; Sirisha Yarlagadda; Connie Ha; Achal S. Achrol; Pui-Yan Kwok; Charles E. McCulloch; Michael T. Lawton; Nerissa U. Ko; Wade S. Smith; William L. Young

Background and Purpose— Cardiac abnormalities occur commonly after subarachnoid hemorrhage (SAH) and may be caused by excessive release of catecholamines from the myocardial sympathetic nerves. We hypothesized that adrenoceptor polymorphisms resulting in greater catecholamine sensitivity would be associated with an increased risk of cardiac injury. Methods— This was a prospective cohort study. The primary outcome variables were the serum level of cardiac troponin I (cTi, abnormal if >1.0 μg/L) and the left ventricular ejection fraction (LVEF, abnormal if <50%). Six adrenoceptor polymorphisms were genotyped: β1AR Arg389Gly, β1AR Ser49Gly, β2AR Gly16Arg, β2AR Gln27Glu, β2AR Thr164Ile, and α2AR del322-325. The effect of each polymorphism on the risk of developing cardiac abnormalities was quantified using multivariable logistic regression. Results— The study included 182 patients. The CC genotype (Arg/Arg) of β1AR Arg389Gly (odds ratio [OR] 3.4, P=0.030) and the CC genotype (Gln/Gln) of β2AR Gln27Glu (OR 3.1, P=0.032) were predictive of cTi release. The presence of the α2AR deletion was predictive of reduced LVEF (OR 4.2, P=0.023). The combination of the β1AR 389 CC and the β2AR 27 CC genotypes resulted in a marked increase in the odds of cTi release (OR 15.5, P=0.012). The combination of the β1AR 389 CC and the α2AR deletion genotypes resulted in a marked increase in the odds of developing a reduced LVEF (OR 10.3, P=0.033). Conclusions— Genetic polymorphisms of the adrenoceptors are associated with an increased risk of cardiac abnormalities after SAH. These data support the hypothesis that cardiac dysfunction after SAH is a form of neurocardiogenic injury.


Annals of Neurology | 2006

Interleukin-6 involvement in brain arteriovenous malformations.

Yongmei Chen; Ludmila Pawlikowska; Jianhua S. Yao; Fanxia Shen; Wenwu Zhai; Achal S. Achrol; Michael T. Lawton; Pui-Yan Kwok; Guo-Yuan Yang; William L. Young

We recently reported that the GG genotype of the interleukin‐6 (IL‐6)–174G>C promoter polymorphism is associated with clinical presentation of intracranial hemorrhage in brain arteriovenous malformation (AVM) patients. In this study, we investigated whether tissue IL‐6 expression was associated with IL‐6–174G>C genotype, and whether IL‐6 was linked to downstream targets involved in angiogenesis and vascular instability. Our results showed that the highest IL‐6 protein levels in brain AVM tissue were associated with IL‐6–174GG genotype (GG: 57.7 ± 20.2; GC: 35.6 ± 26.6; CC: 13.9 ± 10.2pg/mg; p = 0.001). IL‐6 protein levels were increased in AVM tissue from patients with hemorrhagic presentation compared with patients without hemorrhage (55 ± 22 vs 40 ± 27pg/mg; p = 0.038). IL‐6 messenger RNA expression strongly correlated with messenger RNA levels of IL‐1β, tumor necrosis factor‐α, IL‐8, matrix metalloproteinase‐3 (MMP‐3), MMP‐9, and MMP‐12. We further investigated the plausibility of IL‐6 being an upstream cytokine responsible for initiating the angiogenic cascade by cell culture and animal experiments. IL‐6 induced MMP‐3 and MMP‐9 expression and activity in mouse brain and increased proliferation and migration of cerebral endothelial cells. Together, our results suggest that the IL‐6 genotype associated with intracranial hemorrhage modulates IL‐6 expression in brain AVM tissue, which is consistent with the hypothesis that inflammatory processes induce angiogenic activity possibly contributory to brain AVM intracranial hemorrhage. Ann Neurol 2005


Stroke | 2006

Tumor Necrosis Factor-α–238G>A Promoter Polymorphism Is Associated With Increased Risk of New Hemorrhage in the Natural Course of Patients With Brain Arteriovenous Malformations

Achal S. Achrol; Ludmila Pawlikowska; Charles E. McCulloch; K. Y.Trudy Poon; Connie Ha; Jonathan G. Zaroff; S. Claiborne Johnston; Chanhung Lee; Michael T. Lawton; Stephen Sidney; Douglas A. Marchuk; Pui-Yan Kwok; William L. Young

Background and Purpose— Identification of single-nucleotide polymorphisms (SNPs) associated with increased risk of new intracranial hemorrhage (ICH) after brain arteriovenous malformation (BAVM) diagnosis would facilitate risk stratification and identify potential targets for therapeutic intervention. Methods— Patients with BAVM were longitudinally followed. Primary outcome was new ICH after diagnosis; censoring events were last follow-up or any BAVM treatment. We genotyped 4 promoter SNPs in 2 inflammatory cytokine genes: interleukin-6 (IL-6–174G>C; IL-6–572G>C) and tumor necrosis factor-&agr; (TNF-&agr;–238G>A; TNF-&agr;–308G>A). Association of genotype with risk of new ICH was screened using &khgr;2; SNPs associated with new ICH were further characterized using Cox proportional hazards. Results— We genotyped 280 patients (50% female; 59% white, mean±SD age at diagnosis 37±17 years; 40% presenting with ICH). TNF-&agr;–238G>A was associated with increased risk of new ICH after diagnosis (&khgr;2; P=0.003). After adjusting for age, race/ethnicity, and clinical presentation, the risk of new ICH was increased for patients with TNF-&agr;–238 AG genotype (hazard ratio, 4.01; P=0.015). No other SNP was found to be associated with new ICH. Conclusion— A TNF-&agr; SNP was associated with increased risk of new ICH in the natural course of BAVMs. The role of inflammatory cytokines in the pathogenesis of BAVM hemorrhage merits further study.


PLOS Genetics | 2009

Admixture mapping of 15,280 African Americans identifies obesity susceptibility loci on chromosomes 5 and X.

Ching-Yu Cheng; W.H. Linda Kao; Nick Patterson; Arti Tandon; Christopher A. Haiman; Tamara B. Harris; Chao Xing; Esther M. John; Christine B. Ambrosone; Frederick L. Brancati; Josef Coresh; Michael F. Press; Rulan S. Parekh; Michael J. Klag; Lucy A. Meoni; Wen Chi Hsueh; Laura Fejerman; Ludmila Pawlikowska; Matthew L. Freedman; Lina Jandorf; Elisa V. Bandera; Gregory Ciupak; Michael A. Nalls; Ermeg L. Akylbekova; Eric S. Orwoll; Tennille S. Leak; Iva Miljkovic; Rongling Li; Giske Ursin; Leslie Bernstein

The prevalence of obesity (body mass index (BMI) ≥30 kg/m2) is higher in African Americans than in European Americans, even after adjustment for socioeconomic factors, suggesting that genetic factors may explain some of the difference. To identify genetic loci influencing BMI, we carried out a pooled analysis of genome-wide admixture mapping scans in 15,280 African Americans from 14 epidemiologic studies. Samples were genotyped at a median of 1,411 ancestry-informative markers. After adjusting for age, sex, and study, BMI was analyzed both as a dichotomized (top 20% versus bottom 20%) and a continuous trait. We found that a higher percentage of European ancestry was significantly correlated with lower BMI (ρ = −0.042, P = 1.6×10−7). In the dichotomized analysis, we detected two loci on chromosome X as associated with increased African ancestry: the first at Xq25 (locus-specific LOD = 5.94; genome-wide score = 3.22; case-control Z = −3.94); and the second at Xq13.1 (locus-specific LOD = 2.22; case-control Z = −4.62). Quantitative analysis identified a third locus at 5q13.3 where higher BMI was highly significantly associated with greater European ancestry (locus-specific LOD = 6.27; genome-wide score = 3.46). Further mapping studies with dense sets of markers will be necessary to identify the alleles in these regions of chromosomes X and 5 that may be associated with variation in BMI.

Collaboration


Dive into the Ludmila Pawlikowska's collaboration.

Top Co-Authors

Avatar

Helen Kim

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pui-Yan Kwok

University of California

View shared research outputs
Top Co-Authors

Avatar

Michael T. Lawton

Barrow Neurological Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jeffrey Nelson

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Laura N. Bull

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge